What if you could let go of
your transfusions?

ZYNTEGLO™ is an FDA-approved gene therapy that has the potential to free people with beta-thalassemia from regular transfusions.

Results from Clinical Studies

In two phase 3 studies, about 9 out of 10 (89%; 32/36 patients) treated with ZYNTEGLO achieved transfusion independence and had a normal or near-normal median total hemoglobin of 11.5 g/dL.*†

Actor portrayals
A group of people on a meadow releasing balloons.
zyn_patient_icon_adult_ped

Who is ZYNTEGLO for?

ZYNTEGLO is for adult and pediatric patients with beta-thalassemia who require regular blood transfusions.
See how it works
zynteglo-patient-icon-treatment-journey

The treatment journey

ZYNTEGLO is a one-time therapy with a highly coordinated process. Learn more about the treatment journey from start to finish.
Explore the journey
zynteglo-patient-icon-support

Looking for support?

Download a brochure, view FAQs, or learn how my bluebird support Patient Navigators can help guide you through your treatment journey.
Find support
*Transfusion independence (TI) meant that patients achieved a weighted average hemoglobin of ≥9 g/dL without any transfusions for a continuous period of ≥12 months at any time during the study after infusion of ZYNTEGLO.
ZYNTEGLO was evaluated in 41 patients aged 4 to 34 years. Of these 41 patients, 36 were evaluable for TI. Patients were evaluable if they had completed 24 months of follow-up in the phase 3 study, or achieved TI, or won’t achieve TI in the phase 3 study.
Total hemoglobin levels presented about ZYNTEGLO reflect weighted average total hemoglobin during transfusion independence, which is defined as the average across hemoglobin levels taken at each patient visit during the clinical study, factoring in a weighting based on the time duration between study visits. †Normal Hb ranges for healthy individuals from the American College of Clinical Pharmacy:
• 2–9 years: 11.5–14.5 g/dL     • Males 10–17 years: 12.5–16.1 g/dL     • Females 10–17 years: 12–15 g/dL     • Male adults (≥18 years): 13.5–18 g/dL     • Female adults (≥18 years): 12.5–16 g/dL *Transfusion independence (TI) meant that patients achieved a weighted average hemoglobin of ≥9 g/dL without any transfusions for a continuous period of ≥12 months at any time during the study after infusion of ZYNTEGLO.
ZYNTEGLO was evaluated in 41 patients aged 4 to 34 years. Of these 41 patients, 36 were evaluable for TI. Patients were evaluable if they had completed 24 months of follow-up in the phase 3 study, or achieved TI, or won’t achieve TI in the phase 3 study.
Total hemoglobin levels presented about ZYNTEGLO reflect weighted average total hemoglobin during transfusion independence, which is defined as the average across hemoglobin levels taken at each patient visit during the clinical study, factoring in a weighting based on the time duration between study visits. †Normal Hb ranges for healthy individuals from the American College of Clinical Pharmacy:
• 2–9 years: 11.5–14.5 g/dL
• Males 10–17 years: 12.5–16.1 g/dL
• Females 10–17 years: 12–15 g/dL
• Male adults (≥18 years): 13.5–18 g/dL
• Female adults (≥18 years): 12.5–16 g/dL
Stay Connected icon

Stay Connected

Stay Connected

Sign up to receive emails for additional ZYNTEGLO information and resources

Back
to Top